Holen Sie sich die Stockscreener-App
0.70
18.45%
-0.1584
Handel nachbörslich:
.70
Schlusskurs vom Vortag:
$0.8584
Offen:
$0.855
24-Stunden-Volumen:
138.47K
Relative Volume:
2.97
Marktkapitalisierung:
$17.53M
Einnahmen:
$12.00M
Nettoeinkommen (Verlust:
$-63.23M
KGV:
-0.1167
EPS:
-6
Netto-Cashflow:
$-43.02M
1W Leistung:
-33.96%
1M Leistung:
-35.19%
6M Leistung:
-60.23%
1J Leistung:
-29.29%
1-Tages-Spanne:
$0.688
$0.88
1-Wochen-Bereich:
$0.688
$1.15
52-Wochen-Spanne:
$0.688
$2.09
Accelerate Diagnostics Inc Stock (AXDX) Company Profile
Firmenname
Accelerate Diagnostics Inc
Sektor
Branche
Telefon
303-863-8088
Adresse
3950 S. COUNTRY CLUB ROAD #470, TUCSON, AZ
Vergleichen Sie AXDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AXDX
Accelerate Diagnostics Inc
|
0.70 | 17.53M | 12.00M | -63.23M | -43.02M | -6.00 |
|
ABT
Abbott Laboratories
|
130.82 | 226.88B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
99.36 | 146.96B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
364.50 | 142.81B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
87.63 | 112.37B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.91 | 41.85B | 5.72B | 4.17B | 259.90M | 6.97 |
Accelerate Diagnostics Inc Stock (AXDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-03-09 | Herabstufung | Craig Hallum | Buy → Hold |
| 2020-10-08 | Eingeleitet | BTIG Research | Neutral |
| 2020-08-07 | Hochstufung | Craig Hallum | Hold → Buy |
| 2019-09-27 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-11-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-05-24 | Eingeleitet | Craig Hallum | Hold |
| 2017-12-13 | Herabstufung | BTIG Research | Buy → Neutral |
| 2017-07-12 | Fortgesetzt | BTIG Research | Buy |
| 2016-03-24 | Eingeleitet | JP Morgan | Overweight |
| 2015-12-16 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Accelerate Diagnostics Inc Aktie (AXDX) Neueste Nachrichten
AXDX stock touches 52-week low at $0.73 amid market challenges By Investing.com - Investing.com South Africa
AXDX stock touches 52-week low at $0.73 amid market challenges - Investing.com Australia
Accelerate Diagnostics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Accelerate Diagnostics (NASDAQ:AXDX) Now Covered by Analysts at StockNews.com - Defense World
Accelerate Diagnostics Reports 2024 Financial Results - TipRanks
Antimicrobial Susceptibility Testing Market Expecting Huge Demand in Upcoming Years Accelerate Diagnostics - openPR
Accelerate Diagnostics Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
Accelerate Diagnostics seeks FDA clearance for WAVE system By Investing.com - Investing.com Australia
Accelerate Diagnostics seeks FDA clearance for WAVE system - Investing.com India
InventHelp Inventor Develops Modified Single-Serve Coffeemaker (KXK-162) - The Malaysian Reserve
Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance - PR Newswire
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results - PR Newswire
Accelerate Diagnostics Inc. (AXDX) reports earnings - Quartz
Accelerate Diagnostics, Inc SEC 10-K Report - TradingView
Accelerate Diagnostics (AXDX) Expected to Announce Quarterly Earnings on Thursday - Defense World
StockNews.com Initiates Coverage on Accelerate Diagnostics (NASDAQ:AXDX) - Defense World
Major Microbial Identification Market Trend 2025-2034: Automated Systems Transform Microbial Identification... - WhaTech
Accelerate Diagnostics, Inc. to Host Earnings Call - ACCESS Newswire
Accelerate Diagnostics (NASDAQ:AXDX) Earns Hold Rating from Analysts at StockNews.com - Defense World
Accelerate Diagnostics CFO Patience David sells $583 in stock By Investing.com - Investing.com South Africa
Investor Network: Accelerate Diagnostics, Inc. to Host Earnings Call - ACCESS Newswire
Accelerate Diagnostics CFO Patience David sells $583 in stock - Investing.com
Merger Agreement with BioSymetrics to Accelerate Biomarker Identification, Enhance Drug Discovery and Expand Precision Medicine Applications in Advanced Cancer Diagnosis and Treatment | FinancialContent Business Page - Financial Content
Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine - The Manila Times
Renovaro and BioSymetrics Announce Definitive Merger - GlobeNewswire
Masimo (MASI) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
Accelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated at StockNews.com - Defense World
StockNews.com Begins Coverage on Accelerate Diagnostics (NASDAQ:AXDX) - Defense World
Accelerate Diagnostics (NASDAQ:AXDX) Research Coverage Started at StockNews.com - Armenian Reporter
Axos Invest Inc. Purchases 54,293 Shares of Vanguard FTSE Developed Markets ETF (NYSEARCA:VEA) - Armenian Reporter
Antimicrobial Susceptibility Testing Market Advancements Highlighted by Analysis and Forecast to 2033: Mark... - WhaTech
Indaba Capital Management, L.P. Acquires Significant Stake in Ac - GuruFocus.com
BD to separate biosciences and diagnostics business - BioWorld Online
Methicillin-Resistant Staphylococcus Aureus (MRSA) Testing Market Projected to Reach USD 6.5 Billion by 2035 at a 4.2% of CAGR | Future Market Insights, Inc. - Morningstar
Global Antimicrobial Resistance Surveillance Market to Reach USD 9.50 Billion by 2032, Growing at a CAGR of 5.47% - WICZ
Accelerate Diagnostics faces Nasdaq delisting risk By Investing.com - Investing.com South Africa
Accelerate Diagnostics faces Nasdaq delisting risk - Investing.com
Global Antimicrobial Susceptibility Testing Market to Reach USD 4.8 Billion by 2035, Growing at a CAGR of 3.6% | Future Market Insights, Inc. - GlobeNewswire Inc.
Accelerate Diagnostics (NASDAQ:AXDX) Share Price Passes Below 200-Day Moving Average – Time to Sell? - Defense World
Accelerate Diagnostics reports preliminary FY 2024 revenue of $11.7 million - MSN
Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results - PR Newswire
Cofactor Genomics, Inc. Announces CEO Transition in Preparation for Accelerated Commercial Growth and Increased Patient Access for OncoPrism, its Medicare Approved Immunotherapy Test - Business Wire
GRIFFIN ASSET MANAGEMENT, INC. Reduces Holdings in Accelerate Di - GuruFocus.com
Aptitude Secures $10M+ to Accelerate Development of Point-of-Care and Over-the-Counter CT/NG/TV STI Test on Metrix® Platform - PR Newswire
Accelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated by Analysts at StockNews.com - Defense World
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Short Interest Update - Defense World
Finanzdaten der Accelerate Diagnostics Inc-Aktie (AXDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.55%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):